



HTRS/NASTH 2019 SCIENTIFIC SYMPOSIUM
May 9-11, 2019 – Hilton New Orleans Riverside, New Orleans, LA
HTRS/NASTH ABSTRACT ACCEPTANCE POLICY & SUBMISSION INSTRUCTIONS

1. General Information

The abstract/poster session at the HTRS/NASTH 2019 Scientific Symposium (“HTRS/NASTH 2019” or “the meeting”) is a forum for presenting original clinical, translational, or basic science research findings in non-malignant hematology.

HTRS/NASTH accepts abstracts focused on disorders of hemostasis and/or thrombosis from:

- Physicians (MDs and DOs)
- Medical residents and fellows
- Medical students
- PhD investigators and postdoctoral fellows
- Graduate students
- Nurses and nurse practitioners
- Physician assistants
- Pharmacists
- Other healthcare professionals working in non-malignant hematology

Authors of accepted abstracts may present their abstracts as posters during the meeting. Accepted abstracts will be published in the July 2019 online issue of the journal *Haemophilia*. (The exception to this rule is abstracts submitted in the “Informational Only” category described in Section 8, which may be accepted as posters but are not eligible for awards, oral presentations, or publication in *Haemophilia*.) Authors of accepted abstracts who later go on to write a journal article regarding their research are highly encouraged to submit their article to *Haemophilia*.

2. Submission Deadline

Abstracts are due on or before **Monday, January 14, 2019 at 11:59 p.m. ET**. After this deadline, abstracts cannot be revised or resubmitted. Only online submissions through <https://www.conferenceabstracts.com/cfp2/login.asp?EventKey=OIMKFHBK> will be considered.

Accepted abstracts will be published in the July 2019 online issue of the journal *Haemophilia* exactly as submitted. (Authors may make corrections or updates to their posters, but not to abstract submissions after the due date.) Late abstracts will not be accepted. The submission link provided above will be deactivated after **Monday, January 14, 2019 at 11:59 p.m. ET**.

3. HTRS/NASTH Abstract Acceptance Policy

Abstracts will not be accepted by HTRS/NASTH unless the abstract submission itself and the submitting authors meet the following criteria:

- a. Abstracts should describe original work.
- b. Previously-Presented Abstracts
 - i. Unless the exception in 3.b.ii. is met:
Abstracts must contain new data. Abstracts previously presented in a national or international forum may not be submitted without modification; data must be updated or expanded, resulting in a new abstract. Data may not be published before presentation at the meeting. HTRS/NASTH reserves the right to decline a previously published abstract. The same abstract/data that is submitted to HTRS/NASTH cannot be submitted to other meetings before the HTRS/NASTH 2019 Symposium takes place. After the Symposium is over, the abstract may be presented as an encore item to other meetings if their policy allows it.
 - ii. Exception to 3.b.i.: Abstracts/data that have been presented at meetings of less than 1,000 attendees that occur prior to the Symposium may be submitted to the HTRS/NASTH Scientific Symposium for consideration.
- c. The title and body of the abstract must not contain:
 - i. Personal patient information
 - ii. Studies reporting unidentified chemical compounds, drugs, or materials
 - iii. Non-generic drug names (non-generic drug names may be used in a footnote at the bottom of the abstract)
- d. The title of the abstract must not contain:
 - i. Commercial company names (commercial company names may be used in the body of the abstract or as a footnote of the abstract if the name thereby better identifies a product or device)
- e. The submitting author will be asked to certify the following statements prior to uploading an abstract to the online submission site:
 - i. The reported research complies with all applicable animal welfare and human subject regulations.
 - ii. HTRS/NASTH is being given unrestricted, irrevocable permission to publish and/or post the abstract in print material, in online journals partnering with HTRS/NASTH, on the meeting website, and on the HTRS/NASTH website. (The first author retains the abstract's copyright; anyone wishing to use the abstract after the meeting will be instructed to contact the first author for permission.)
 - iii. The presenting author must be willing to answer all questions from the audience in good faith if the abstract is selected for oral presentation.

4. Review and Selection Process

All abstracts undergo blind peer review. The HTRS/NASTH Scientific Review Committee evaluates abstracts based on scientific content, applicability to meeting topics and session themes, novelty, writing quality, and overall scientific merit. The Committee will give equal consideration to hemostasis and thrombosis submissions.

5. HTRS/NASTH Travel Awards

HTRS/NASTH Travel Awards cover the cost of airfare, ground transportation, lodging for two nights, and/or meals on travel days subject to a per diem rate, to attend the meeting, up to a total of \$1,500 USD. Travel Award recipients also receive waived meeting registration fees.

HTRS/NASTH will offer nine Travel Awards to investigators who meet the following criteria:

- Up to eight awards will be given to the first authors of the highest scoring abstracts submitted by trainees or early career investigators working at non-commercial institutions (please refer to the definition of “trainees” and “early career investigators” below)
- At least one award will be given to the first author of the highest scoring abstract submitted by an allied health professional at any stage in his/her career working in non-malignant hematology at a non-commercial institution

HTRS/NASTH defines “trainees” as:

- **Medical fellows:** MDs or DOs enrolled in accredited fellowship training programs in the U.S. or Canada. Fellows must be:
 - In training for a career in hemostasis and/or thrombosis
 - OR
 - In training for a career that will have a substantial component of, or overlap with, the disciplines of hemostasis and/or thrombosis (such as ob/gyn or cardiology)
- **Postdoctoral fellows:** PhDs pursuing additional academic research in non-malignant hematology
- **Medical residents** interested in non-malignant hematology as a career
- **Medical students** interested in non-malignant hematology as a career
- **Graduate students** interested in pursuing research in non-malignant hematology

HTRS/NASTH defines “early career investigators” as:

- **Junior attending and junior faculty** (MDs, DOs, PhDs) working in non-commercial institutions who are:
 - Within five years of completing training for a career in hemostasis and/or thrombosis at the time of the abstract submission deadline
 - OR
 - Within five years of completing training for a career that will have a substantial component of, or overlap with, the disciplines of hemostasis and/or thrombosis (such as ob/gyn or cardiology) at the time of the abstract submission deadline

HTRS/NASTH defines “allied health professionals” as including, but not limited to, any of the following who are interested in pursuing research in non-malignant hematology:

- **Nurses/Nurse Practitioners**
- **Physician Assistants**
- **Pharmacists**
- **Physical Therapists**
- **Medical Technologists or Other Laboratory Professionals**
- **Genetic Counselors**
- **Social Workers**

6. Oral Presentations for the Top Four Travel Award Recipients

The top four Travel Award recipients in the Trainee/Early Career Investigator category who submit the highest scoring abstracts will be invited to give oral presentations during the Oral Abstract Session on Friday, May 10 from 11:00 a.m. to 12:15 p.m. (The Travel Award for allied health professionals will not include an oral presentation component in HTRS/NASTH 2019.)

- Presenting authors should be the first authors of Travel Award abstracts.
- Presenting authors will be given 10 minutes to discuss their abstract, immediately followed by a three-minute question-and-answer period.
- Details about oral abstract presentation and instructions for preparing slides will be sent to the presenting author in early March 2019 along with poster presentation instructions.
- Travel Award recipients who elect to make oral presentations may also present their abstract as a poster during the “Poster Presentation” Session on Friday, May 10 (hemostasis posters) or Saturday, May 11, 2019 (thrombosis posters).

7. “Abstracts of Distinction”

The top scoring abstracts submitted by investigators who are not eligible for the Trainee/Early Career Investigator category and who work for non-commercial institutions will be recognized as “Abstracts of Distinction.” Authors of abstracts receiving this designation may be invited to give an oral presentation during the Oral Abstract Session on Friday, May 10 from 11:00 a.m. to 12:15 p.m.

- It is preferred, but not mandated, that the presenting author be the first author of the abstract submitted in this category.
- Presenters will be given 10 minutes to discuss their abstracts, immediately followed by a three-minute question-and-answer period.
- Details about oral abstract presentation and instructions for preparing slides will be sent to the presenting author in early March 2019 along with poster presentation instructions.
- Authors of “Abstracts of Distinction” who elect to make oral presentations may also present their abstracts as posters during the “Poster Presentation” Session on Friday, May 10 (hemostasis posters) or Saturday, May 11, 2019 (thrombosis posters).

8. “Informational Only” Abstracts

Abstracts may be submitted for informational purposes only to be displayed as posters at the conference.

- “Informational Only” abstracts are not eligible for Travel Awards, designation as “Abstracts of Distinction,” oral presentations, or publication in *Haemophilia*.
- Informational Only abstracts generally do not contain original data.
- Examples of informational abstracts include: news about a new or existing registry, news about a new or existing study, news about a new society or meeting being organized, information about a novel practice or service (i.e. use of telemedicine for consults), or a single case report/very small case series (of note, for case reports and series, exceptions may be made if the abstract presents particularly compelling/new information on a rare disorder).

9. Preparing Your Abstract

Please follow these instructions to prepare your abstract/s for submission. Proofread carefully to avoid errors before submission.

- a. Language: English
- b. Authors: Last name, first name, degrees, affiliations, city, state, country, and contact information (only the names of the first six authors will appear, over six will be et al)
- c. Maximum of 3,000 characters including spaces (not including the title, authors, or affiliations)
- d. Abstract text should preferably be in a “structured abstract” form with sections clearly marked Objectives, Methods, Results, and Conclusions.
- e. Maximum of 2 relevant tables or figures. Please submit figures in .jpg format at the highest resolution possible; a minimum of 600 dpi is recommended. Figures that do not meet these minimum formatting requirements may be excluded from publication.
- f. References must be included as parenthetical in-text citations: first author, et al, journal and year (e.g. Cruz D, et al. Blood 2012)
- g. Abstracts containing non-generic drug names in the title or body of the abstract, personal patient information, or reporting studies with unidentified chemical compounds, drugs, or materials will not be accepted. (Non-generic drug names may be used in a footnote at the bottom of the abstract but not in the title or body of the abstract.) Abstracts containing drug manufacturers’ company names in the title of the abstract will not be accepted, but a drug manufacturer’s company name can appear in the body or footnote of the abstract if it thereby better identifies a product or device.
- h. Full contact information for the corresponding author. (Please ensure that your email address is accurate, as all correspondence will be sent via email.)

10. Poster Presentation Sessions and General Viewing of Posters

The Poster Presentation Sessions will be held in the HTRS/NASTH 2019 Exhibit Hall where poster presenters must be on hand to answer questions about their posters on these dates and times:

- Hemostasis Poster Session: Friday, May 10, 2019 from 4:45 p.m. to 6:00 p.m.
- Thrombosis Poster Session: Saturday, May 11, 2019 from 8:30 a.m. to 9:45 a.m.

Hemostasis posters will be available for general viewing on Friday, May 10, 2019 from 9:30 a.m. to 6:00 p.m. and thrombosis posters will be available for general viewing on Saturday, May 11, 2019 from 8:30 a.m. to 11:00 a.m. Note that these times may be subject to change; submitting authors should refer to the instructions that will be sent to them in their notification letters for further details.

11. Responsibilities of Abstract/Poster Presenters

Presenting Authors Who are Travel Award Recipients

- HTRS/NASTH will register Travel Award recipients for the meeting and reserve lodging within the HTRS/NASTH 2019 Room Block for two nights at the meeting hotel.
- Travel Award recipients must make their own airfare and ground travel arrangements. Travel Awards provide up to \$1,500 USD to be applied toward airfare, ground travel, two nights' lodging, and/or meals on travel days up not to exceed \$65 per travel day including gratuities (\$15 for breakfast, \$20 for lunch, and/or \$30 for dinner).

Presenting Authors Not Selected for Travel Awards

- Must register to attend the meeting.
- Are responsible for all expenses related to participating in the meeting, including registration fees, transportation, lodging, and any meals outside of those provided by HTRS/NASTH as part of the general conference.

12. Notification

Notification of abstract acceptance for poster presentation, Travel Awards, and Abstracts of Distinction will be made by the first week of March 2019.

13. For More Information

Questions regarding HTRS/NASTH 2019 abstract submission should be directed to Heather Seasholtz at htrs@talley.com.